Large randomized, controlled clinical trials in nephropathic patients have raised safety concerns associated with high-dose ESA therapy and high Hb targets, citing death and hospitalization for chronic heart failure and fatal or nonfatal stroke [36,37]. The gene discussed is GSTM1; the disease is stroke disorder.